Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Malignant Melanoma

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 102 articles: HTML format Text format

Single Articles

February 2010
1. SEGURA MF , Belitskaya-Levy I, Rose AE, Zakrzewski J, et al
   Melanoma MicroRNA Signature Predicts Post-Recurrence Survival.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   January 2010
2. KIRKWOOD JM , Lorigan P, Hersey P, Hauschild A, et al
   Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   December 2009
3. SU Y , Amiri KI, Horton LW, Yu Y, et al
   A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets.
   Clin Cancer Res. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. AMARAVADI RK , Schuchter LM, McDermott DF, Kramer A, et al
   Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.
   Clin Cancer Res. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. TOH HC , Wang WW, Chia WK, Kvistborg P, et al
   Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients.
   Clin Cancer Res. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. DAVIES MA , Stemke-Hale K, Lin E, Tellez C, et al
   Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.
   Clin Cancer Res. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   November 2009
7. GOODSON AG , Cotter MA, Cassidy P, Wade M, et al
   Use of Oral N-Acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress: Towards a Novel Paradigm for Melanoma Chemoprevention.
   Clin Cancer Res. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. SLINGLUFF CL JR , Petroni GR, Olson WC, Smolkin ME, et al
   Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial.
   Clin Cancer Res. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
9. FARIES MB , Hsueh EC, Ye X, Hoban M, et al
   Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine.
   Clin Cancer Res. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. CONWAY C , Mitra A, Jewell R, Randerson-Moor J, et al
    Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free Survival.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. KASHANI-SABET M , Venna S, Nosrati M, Rangel J, et al
    A Multimarker Prognostic Assay for Primary Cutaneous Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2009
12. HERSEY P , Watts RN, Zhang XD, Hackett J, et al
    Metabolic Approaches to Treatment of Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. LIN H , Wong RP, Martinka M, Li G, et al
    Loss of SNF5 Expression Correlates with Poor Patient Survival in Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. RIBAS A , Comin-Anduix B, Chmielowski B, Jalil J, et al
    Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
    Clin Cancer Res. 2009;15:6267-76.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
15. PANDHA HS , Heinemann L, Simpson GR, Melcher A, et al
    Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. HANK JA , Gan J, Ryu H, Ostendorf A, et al
    Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults With Melanoma and Children With Neuroblastoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. YVON E , Del Vecchio M, Savoldo B, Hoyos V, et al
    Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. JILAVEANU LB , Zito CR, Aziz SA, Conrad PJ, et al
    C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
19. PASCHEN A , Sucker A, Hill B, Moll I, et al
    Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
    Clin Cancer Res. 2009;15:5208-15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. WEBER J , Thompson JA, Hamid O, Minor D, et al
    A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
21. CRUZ-MUNOZ W , Man S, Kerbel RS
    Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy Regimens.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. LOTEM M , Machlenkin A, Hamburger T, Nissan A, et al
    Autologous Melanoma Vaccine Induces Antitumor and Self-Reactive Immune Responses That Affect Patient Survival and Depend on MHC Class II Expression on Vaccine Cells.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. PRESTWICH RJ , Ilett EJ, Errington F, Diaz RM, et al
    Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.
    Clin Cancer Res. 2009;15:4374-81.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
24. ZHAO F , Falk C, Osen W, Kato M, et al
    Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. CARPENTER EL , Mick R, Rech AJ, Beatty GL, et al
    Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. MORTARINI R , Vegetti C, Molla A, Arienti F, et al
    Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
27. CHERNOFF KA , Bordone L, Horst B, Simon K, et al
    GAB2 Amplifications Refine Molecular Classification of Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
28. SCHWARTZ AL , Malgor R, Dickerson E, Weeraratna AT, et al
    Phenylmethimazole Decreases Toll-Like Receptor 3 and Noncanonical Wnt5a Expression in Pancreatic Cancer and Melanoma Together with Tumor Cell Growth and Migration.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. YIP D , Le MN, Chan JL, Lee JH, et al
    A Phase 0 Trial of Riluzole in Patients with Resectable Stage III and IV Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
30. SCHICHER N , Paulitschke V, Swoboda A, Kunstfeld R, et al
    Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma.
    Clin Cancer Res. 2009;15:3495-502.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. CARRENO BM , Garbow JR, Kolar GR, Jackson EN, et al
    Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
    Clin Cancer Res. 2009;15:3277-86.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. BONEHILL A , Van Nuffel AM, Corthals J, Tuyaerts S, et al
    Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
33. AZIZ SA , Davies M, Pick E, Zito C, et al
    Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. LEE CH , Chiang YH, Chang SE, Chong CL, et al
    Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
    Clin Cancer Res. 2009;15:2756-66.
    PubMed     Text format     Related articles    Abstract available
    
    
    
35. KLEIN O , Ebert LM, Nicholaou T, Browning J, et al
    Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
    Clin Cancer Res. 2009;15:2507-13.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
36. KITAGO M , Martinez SR, Nakamura T, Sim MS, et al
    Regulation of RUNX3 Tumor Suppressor Gene Expression in Cutaneous Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. O'REILLY KE , Warycha M, Davies MA, Rodrik V, et al
    Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. FIROZ EF , Warycha M, Zakrzewski J, Pollens D, et al
    Association of MDM2 SNP309, Age of Onset, and Gender in Cutaneous Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
39. DAUD AI , Dawson J, Deconti RC, Bicaku E, et al
    Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. VERDIJK P , Aarntzen EH, Lesterhuis WJ, Boullart AC, et al
    Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. WALKER EB , Miller W, Haley D, Floyd K, et al
    Characterization of the Class I-Restricted gp100 Melanoma Peptide-stimulated Primary Immune Response in Tumor-Free Vaccine-draining Lymph Nodes and Peripheral Blood.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. REVSKAYA E , Jongco AM, Sellers RS, Howell RC, et al
    Radioimmunotherapy of Experimental Human Metastatic Melanoma with Melanin-Binding Antibodies and in Combination with Dacarbazine.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
43. SINGH S , Sadanandam A, Nannuru KC, Varney ML, et al
    Small-Molecule Antagonists for CXCR2 and CXCR1 Inhibit Human Melanoma Growth by Decreasing Tumor Cell Proliferation, Survival, and Angiogenesis.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
44. NICHOLAOU T , Ebert LM, Davis ID, McArthur GA, et al
    Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
45. DAVIS ID , Brady B, Kefford RF, Millward M, et al
    Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. LI B , VanRoey M, Wang C, Chen TH, et al
    Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Clin Cancer Res. 2009;15:1623-34.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
47. NEVALA WK , Vachon CM, Leontovich AA, Scott CG, et al
    Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
48. TANEMURA A , Terando AM, Sim MS, van Hoesel AQ, et al
    CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. KIRKWOOD JM , Lee S, Moschos SJ, Albertini MR, et al
    Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
    Clin Cancer Res. 2009;15:1443-51.
    PubMed     Text format     Related articles    Abstract available
    
    
    
50. HELFRICH I , Edler L, Sucker A, Thomas M, et al
    Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
    Clin Cancer Res. 2009;15:1384-92.
    PubMed     Text format     Related articles    Abstract available
    
    
    
51. HILL DS , Martin S, Armstrong JL, Flockhart R, et al
    Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma.
    Clin Cancer Res. 2009;15:1192-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
52. SHARMA A , Sharma AK, Madhunapantula SV, Desai D, et al
    Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
53. JILAVEANU L , Zito C, Lee SJ, Nathanson KL, et al
    Expression of sorafenib targets in melanoma patients treated with Carboplatin, Paclitaxel and sorafenib.
    Clin Cancer Res. 2009;15:1076-85.
    PubMed     Text format     Related articles    Abstract available
    
    
    
54. LU W , Xiong C, Zhang G, Huang Q, et al
    Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres.
    Clin Cancer Res. 2009;15:876-86.
    PubMed     Text format     Related articles    Abstract available
    
    
    
55. FUNG JM , Smith R, Brown MA, Lau SH, et al
    Identification and characterization of a novel melanoma tumor suppressor gene on human chromosome 6q21.
    Clin Cancer Res. 2009;15:797-803.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
56. AUGUSTINE CK , Yoo JS, Potti A, Yoshimoto Y, et al
    Genomic and molecular profiling predicts response to temozolomide in melanoma.
    Clin Cancer Res. 2009;15:502-10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
57. KOTTKE T , Thompson J, Diaz RM, Pulido J, et al
    Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.
    Clin Cancer Res. 2009;15:561-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
58. RIBAS A , Comin-Anduix B, Economou JS, Donahue TR, et al
    Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade.
    Clin Cancer Res. 2009;15:390-399.
    PubMed     Text format     Related articles    Abstract available
    
    
    
59. HOFMANN UB , Kauczok-Vetter CS, Houben R, Becker JC, et al
    Overexpression of the KIT/SCF in Uveal Melanoma Does Not Translate into Clinical Efficacy of Imatinib Mesylate.
    Clin Cancer Res. 2009;15:324-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
60. WANG W , Edington HD, Rao UN, Jukic DM, et al
    Effects of High-Dose IFN{alpha}2b on Regional Lymph Node Metastases of Human Melanoma: Modulation of STAT5, FOXP3, and IL-17.
    Clin Cancer Res. 2008;14:8314-20.
    PubMed     Text format     Related articles    Abstract available
    
    
    
61. SOLIT DB , Osman I, Polsky D, Panageas KS, et al
    Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma.
    Clin Cancer Res. 2008;14:8302-8307.
    PubMed     Text format     Related articles    Abstract available
    
    
    
62. WAGNER S , Krepler C, Allwardt D, Latzka J, et al
    Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine.
    Clin Cancer Res. 2008;14:8178-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    
63. JOHNSON TS , Mahnke K, Storn V, Schonfeld K, et al
    Inhibition of Melanoma Growth by Targeting of Antigen to Dendritic Cells via an Anti-DEC-205 Single-Chain Fragment Variable Molecule.
    Clin Cancer Res. 2008;14:8169-77.
    PubMed     Text format     Related articles    Abstract available
    
    
    
64. JIANG X , Zhou J, Yuen NK, Corless CL, et al
    Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma.
    Clin Cancer Res. 2008;14:7726-32.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
65. WALTHER W , Siegel R, Kobelt D, Knosel T, et al
    Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer.
    Clin Cancer Res. 2008;14:7545-53.
    PubMed     Text format     Related articles    Abstract available
    
    
    
66. DE SNOO FA , Bishop DT, Bergman W, van Leeuwen I, et al
    Increased Risk of Cancer Other Than Melanoma in CDKN2A Founder Mutation (p16-Leiden)-Positive Melanoma Families.
    Clin Cancer Res. 2008;14:7151-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
67. BEADLING C , Jacobson-Dunlop E, Hodi FS, Le C, et al
    KIT Gene Mutations and Copy Number in Melanoma Subtypes.
    Clin Cancer Res. 2008;14:6821-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
68. KINDERS RJ , Hollingshead M, Khin S, Rubinstein L, et al
    Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
    Clin Cancer Res. 2008;14:6877-85.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2008
69. NG B , Zakrzewski J, Warycha M, Christos PJ, et al
    Shedding of Distinct Cryptic Collagen Epitope (HU177) in Sera of Melanoma Patients.
    Clin Cancer Res. 2008;14:6253-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
70. SCHWARTZ MA , McRoberts K, Coyner M, Andarawewa KL, et al
    Integrin Agonists as Adjuvants in Chemotherapy for Melanoma.
    Clin Cancer Res. 2008;14:6193-6197.
    PubMed     Text format     Related articles    Abstract available
    
    
    
71. CAO Q , Cai W, Niu G, He L, et al
    Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasis.
    Clin Cancer Res. 2008;14:6137-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2008
72. DA FORNO PD , Pringle JH, Hutchinson P, Osborn J, et al
    WNT5A expression increases during melanoma progression and correlates with outcome.
    Clin Cancer Res. 2008;14:5825-32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
73. KONG LY , Abou-Ghazal MK, Wei J, Chakraborty A, et al
    A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.
    Clin Cancer Res. 2008;14:5759-68.
    PubMed     Text format     Related articles    Abstract available
    
    
    
74. BHANDARKAR SS , Bromberg J, Carrillo C, Selvakumar P, et al
    Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.
    Clin Cancer Res. 2008;14:5743-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
75. ZIMMERER JM , Lesinski GB, Ruppert AS, Radmacher MD, et al
    Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha.
    Clin Cancer Res. 2008;14:5900-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
76. SMITH FO , Downey SG, Klapper JA, Yang JC, et al
    Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
    Clin Cancer Res. 2008;14:5610-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2008
77. WALKER EB , Haley D, Petrausch U, Floyd K, et al
    Phenotype and Functional Characterization of Long-term gp100-Specific Memory CD8+ T Cells in Disease-Free Melanoma Patients Before and After Boosting Immunization.
    Clin Cancer Res. 2008;14:5270-5283.
    PubMed     Text format     Related articles    Abstract available
    
    
    
78. MENARD C , Ghiringhelli F, Roux S, Chaput N, et al
    Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Clin Cancer Res. 2008;14:5242-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
79. RESCHKE M , Mihic-Probst D, van der Horst EH, Knyazev P, et al
    HER3 Is a Determinant for Poor Prognosis in Melanoma.
    Clin Cancer Res. 2008;14:5188-97.
    PubMed     Text format     Related articles    Abstract available
    
    
    
80. JOHN T , Black MA, Toro TT, Leader D, et al
    Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma.
    Clin Cancer Res. 2008;14:5173-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2008
81. MOLENKAMP BG , Sluijter BJ, van Leeuwen PA, Santegoets SJ, et al
    Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients.
    Clin Cancer Res. 2008;14:4532-42.
    PubMed     Text format     Related articles    Abstract available
    
    
    
82. ULMER A , Beutel J, Susskind D, Hilgers RD, et al
    Visualization of Circulating Melanoma Cells in Peripheral Blood of Patients with Primary Uveal Melanoma.
    Clin Cancer Res. 2008;14:4469-4474.
    PubMed     Text format     Related articles    Abstract available
    
    
    
83. STRIETH S , Eichhorn ME, Werner A, Sauer B, et al
    Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin.
    Clin Cancer Res. 2008;14:4603-11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
84. FRIEDLOS F , Lehouritis P, Ogilvie L, Hedley D, et al
    Attenuated salmonella targets prodrug activating enzyme carboxypeptidase g2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy.
    Clin Cancer Res. 2008;14:4259-66.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2008
85. ONKEN MD , Worley LA, Harbour JW
    A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis.
    Clin Cancer Res. 2008;14:3737-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    
86. TRAN MA , Smith CD, Kester M, Robertson GP, et al
    Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
    Clin Cancer Res. 2008;14:3571-81.
    PubMed     Text format     Related articles    Abstract available
    
    
    
87. GOTO Y , Ferrone S, Arigami T, Kitago M, et al
    Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes.
    Clin Cancer Res. 2008;14:3401-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
88. LI B , VanRoey M, Triebel F, Jooss K, et al
    Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy.
    Clin Cancer Res. 2008;14:3545-54.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2008
89. KLINE J , Brown IE, Zha YY, Blank C, et al
    Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of b16 melanoma.
    Clin Cancer Res. 2008;14:3156-67.
    PubMed     Text format     Related articles    Abstract available
    
    
    
90. MOORE SR , Persons DL, Sosman JA, Bobadilla D, et al
    Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431).
    Clin Cancer Res. 2008;14:2927-35.
    PubMed     Text format     Related articles    Abstract available
    
    
    
91. LEE DY , Park K, Kim SK, Park RW, et al
    Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis.
    Clin Cancer Res. 2008;14:2841-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2008
92. SALEEM M , Maddodi N, Abu Zaid M, Khan N, et al
    Lupeol Inhibits Growth of Highly Aggressive Human Metastatic Melanoma Cells In vitro and In vivo by Inducing Apoptosis.
    Clin Cancer Res. 2008;14:2119-27.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2008
93. LEE TY , Tjin Tham Sjin RM, Movahedi S, Ahmed B, et al
    Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.
    Clin Cancer Res. 2008;14:1487-93.
    PubMed     Text format     Related articles    Abstract available
    
    
    
94. ZIMMERER JM , Lehman AM, Ruppert AS, Noble CW, et al
    IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2.
    Clin Cancer Res. 2008;14:1438-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2008
95. AVERY-KIEJDA KA , Zhang XD, Adams LJ, Scott RJ, et al
    Small Molecular Weight Variants of p53 Are Expressed in Human Melanoma Cells and Are Induced by the DNA-Damaging Agent Cisplatin.
    Clin Cancer Res. 2008;.
    PubMed     Text format     Related articles    Abstract available   Free Full Text
    
    
    
96. BAKALIAN S , Marshall JC, Logan P, Faingold D, et al
    Molecular pathways mediating liver metastasis in patients with uveal melanoma.
    Clin Cancer Res. 2008;14:951-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
97. DUMMER R , Hauschild A, Becker JC, Grob JJ, et al
    An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma.
    Clin Cancer Res. 2008;14:856-64.
    PubMed     Text format     Related articles    Abstract available
    
    
    
98. FAINGOLD D , Marshall JC, Antecka E, Di Cesare S, et al
    Immune Expression and Inhibition of Heat Shock Protein 90 in Uveal Melanoma.
    Clin Cancer Res. 2008;14:847-855.
    PubMed     Text format     Related articles    Abstract available
    
    
    
99. NEGIN B , Panka D, Wang W, Siddiqui M, et al
    Effect of melanoma on immune function in the regional lymph node basin.
    Clin Cancer Res. 2008;14:654-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
100. AMERSI FF , Terando AM, Goto Y, Scolyer RA, et al
     Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine.
     Clin Cancer Res. 2008;14:638-45.
     PubMed     Text format     Related articles    Abstract available
     
     
     
101. RICHMOND A
     CCR9 Homes Metastatic Melanoma Cells to the Small Bowel.
     Clin Cancer Res. 2008;14:621-3.
     PubMed     Text format     Related articles   
     
     
     January 2008
102. QIAO J , Wang H, Kottke T, White C, et al
     Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
     Clin Cancer Res. 2008;14:259-69.
     PubMed     Text format     Related articles    Abstract available
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: